Cargando…
Oxaliplatin-DNA adduct formation in white blood cells of cancer patients
In this study, we investigated the kinetics of oxaliplatin-DNA adduct formation in white blood cells of cancer patients in relation to efficacy as well as oxaliplatin-associated neurotoxicity. Thirty-seven patients with various solid tumours received 130 mg m(−2) oxaliplatin as a 2-h infusion. Oxali...
Autores principales: | Pieck, A C, Drescher, A, Wiesmann, K G, Messerschmidt, J, Weber, G, Strumberg, D, Hilger, R A, Scheulen, M E, Jaehde, U |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2441951/ https://www.ncbi.nlm.nih.gov/pubmed/18506148 http://dx.doi.org/10.1038/sj.bjc.6604387 |
Ejemplares similares
-
Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells
por: Temmink, O H, et al.
Publicado: (2007) -
Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells
por: Roberts, D L, et al.
Publicado: (2009) -
Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation
por: Balin-Gauthier, D, et al.
Publicado: (2008) -
A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients
por: Lesterhuis, W J, et al.
Publicado: (2010) -
Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer
por: Baba, H, et al.
Publicado: (2012)